Quit Smoking: Optimizing Health Promotion Strategy
- Disease/Condition
- Smoking Cessation
- Drug/Device/Intervention
- Nicotine Replace Therapy (NRT) sampling
- Study type
- Interventional
- Intervention type
- other
- Primary sponsor
- The University of Hong Kong
- Location
- Hong Kong, China
- Phase
- N/A
- Start date
- Jun 01, 2023
- End date
- Jan 31, 2024
- Enrollment
- 160 participants
Incremental Behaviour Change toward Smoking cessation (IBC-S)
The goal of this factorial trail is to to optimize an intervention package to enhance quit
 attempt preparations, quit attempts, and tobacco abstinence among smokers without a plan to
 quit.
 
 The main questions it aims to answer are:
 
 - What are the main effects of the four intervention components for increasing quit
 attempt preparation?
 
 - Are there synergistic or antagonistic interactions between components?
 
 - Does chat-based instant message or chatbot enhance the effects of nicotine replacement
 therapy sampling and/or simple exercise education in increasing motivation to quit?
 
 - When participants experienced successful quitting by using the nicotine replacement
 therapy patch, will other tools, such as simple exercise education, chat-based instant
 messages, or chatbot, could help in the process and strengthen the effects of the
 nicotine replacement therapy patch and solve the possible problems they may encounter in
 using nicotine replacement therapy patch in a timely manner?
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06077058
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06077058 through Pure Global AI's free database. This phase not specified trial is sponsored by The University of Hong Kong and is currently Recruiting. The study focuses on Smoking Cessation. Target enrollment is 160 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.